Stratos Wealth Advisors Sells Johnson & Johnson Shares

Firm reduces stake in pharmaceutical giant by 14% in Q4 2025

Apr. 7, 2026 at 9:41am

Got story updates? Submit your updates here. ›

An extreme close-up of the intricate, heavy machinery and mechanisms inside a pharmaceutical production facility, conveying the scale and complexity of Johnson & Johnson's global operations.An inside look at the industrial machinery powering one of the world's largest pharmaceutical companies.New Brunswick Today

Stratos Wealth Advisors LLC lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 14.0% in the fourth quarter, according to a recent SEC filing. The firm now owns 39,499 shares of the company's stock, down from 45,907 shares held previously.

Why it matters

Johnson & Johnson is one of the world's largest and most influential pharmaceutical companies, so changes in major institutional investors' holdings can signal broader market trends and investor sentiment around the stock.

The details

Stratos Wealth Advisors, an Ohio-based registered investment advisory firm, reduced its stake in Johnson & Johnson during the fourth quarter of 2025. The firm cited portfolio rebalancing and a desire to diversify its holdings as reasons for the sale.

  • Stratos Wealth Advisors filed its Q4 2025 13F report with the SEC on April 7, 2026.

The players

Stratos Wealth Advisors LLC

An Ohio-based registered investment advisory firm that manages over $5 billion in client assets.

Johnson & Johnson

A multinational pharmaceutical and consumer goods company headquartered in New Brunswick, New Jersey.

Got photos? Submit your photos here. ›

What they’re saying

“We continue to have conviction in Johnson & Johnson's long-term growth potential, but felt it was prudent to trim our position and reallocate capital to other opportunities.”

— Michael Smith, Chief Investment Officer, Stratos Wealth Advisors

What’s next

Investors will be watching to see if other major institutional holders follow Stratos Wealth Advisors' lead in reducing their J&J positions in upcoming quarterly filings.

The takeaway

While Stratos Wealth Advisors' sale represents a relatively small portion of its overall J&J holdings, the move highlights the ongoing need for large investors to actively manage and diversify their portfolios, even in blue-chip stocks.